Relmada Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Relmada Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Relmada Therapeutics, Inc. made a loss over the last year. Relmada Therapeutics, Inc. owes $0.06 for every $1 it owns. Relmada Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRelmada Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.70The share price is 1.70 times Relmada Therapeutics, Inc.'s book value per share, lower than 64% of Healthcare companies in United States.
Market cap
$351 MThe total market value of all of Relmada Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 50% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$207 MWhat Relmada Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.94Net worth divided by the number of shares. The share price of $3.29 is 1.7 times this, which is the P/B above.
Return on equity (ROE)
-55.7%Relmada Therapeutics, Inc. lost 55.7% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
Owes vs Owns
0.06×Relmada Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneRelmada Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossRelmada Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Relmada Therapeutics, Inc.: $351 M ÷ $207 M (30 Jun 2026) = 1.7.
What is Relmada Therapeutics, Inc.'s return on equity?
Relmada Therapeutics, Inc. lost 55.7% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
How much does Relmada Therapeutics, Inc. owe compared with what it owns?
Relmada Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does Relmada Therapeutics, Inc. pay a dividend?
No. Relmada Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.